Efficacy and Safety of Osimertinib Adjuvant Therapy in High-risk Stage I EGFRm NSCLC After Complete Resection(OSTAR): a Prospective, Single-arm Study
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSTAR
Most Recent Events
- 30 Apr 2025 Results (data cutoff date: 29 Oct 2024; n=70) presented at the 116th Annual Meeting of the American Association for Cancer Research
- 18 Jan 2023 New trial record